Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + erlotinib
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of docetaxel, a taxane chemotherapy agent, and erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination has been studied in various dosing schedules, particularly intercalated regimens designed to achieve pharmacodynamic separation between the two agents. Clinical trials have investigated this combination for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinomas (HNSCC), showing promising efficacy in specific settings.
- Brand names
- TarcevaTaxotere
- Other names
- none
02
Targets
MicrotubuleERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on docetaxel + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + erlotinib.